Least developed countries vs Mauritania: Access to anti-retroviral drugs, male
Least developed countries
80.9%
in 2024
Mauritania
97.0%
in 2024
Least developed countries rank
2nd
Mauritania rank
2nd
Access to anti-retroviral drugs, male over time
- Least developed countries
- Mauritania
How they compare
Mauritania currently reports 97.0% against 80.9% in Least developed countries, a difference of 16.1%.
That makes Mauritania's figure about 1.2 times Least developed countries's.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Mauritania ahead.
Least developed countries ranks 2nd and Mauritania ranks 2nd of 19 groups.
Across the 3 decades both report, Least developed countries averaged higher in 2 and Mauritania in 1.
Head to head by decade
| Decade | Least developed countries | Mauritania | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.7% | 3.7% | 2.0% | Least developed countries |
| 2010s | 40.1% | 33.4% | 6.7% | Least developed countries |
| 2020s | 73.4% | 79.4% | 6.0% | Mauritania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Least developed countries or Mauritania?
- Mauritania, at 97.0% against 80.9% in Least developed countries as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Least developed countries and Mauritania?
- 16.1%, with Mauritania ahead.
- How many years of comparable data are there for Least developed countries and Mauritania?
- 25 years are reported by both, from 2000 to 2024.
- How do Least developed countries and Mauritania rank globally for access to anti-retroviral drugs, male?
- Least developed countries ranks 2nd and Mauritania ranks 2nd of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.